



## Clinical trial results:

### A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

#### Summary

EudraCT number	2017-002190-20
Trial protocol	HR
Global end of trial date	22 January 2019

#### Results information

Result version number	v2 (current)
This version publication date	29 February 2020
First version publication date	29 December 2019
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Update for alignment with revised clinicaltrials.gov results posting

#### Trial information

##### Trial identification

Sponsor protocol code	331-201-00081
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03257865
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor organisation address	2440 Research Boulevard, Rockville, MD, United States, 20850
Public contact	Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., +1-609 524-6788, clinicaltransparency@otsuka-us.com
Scientific contact	Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., +1-609 524-6788, clinicaltransparency@otsuka-us.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 September 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 January 2019
Global end of trial reached?	Yes
Global end of trial date	22 January 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate the efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in participants with a diagnosis of bipolar I disorder.

Protection of trial subjects:

This trial was conducted in accordance with International Council on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which the trial was conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 September 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Croatia: 1
Country: Number of subjects enrolled	Ukraine: 93
Country: Number of subjects enrolled	United States: 239
Worldwide total number of subjects	333
EEA total number of subjects	1

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	333
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The trial population consisted of adult participants (18 to 65 years) diagnosed with bipolar I disorder displaying an acute manic episode with or without mixed features requiring hospitalization. One participant randomized to brexpiprazole was not treated and excluded from the safety analysis set.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Blinding implementation details:

Treatment assignments were based on a computer-generated randomization code. Sponsor personnel, including those involved in monitoring, data management, and data analysis, did not have access to the treatment code during the trial.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Brexpiprazole

Arm description:

Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligram (mg)/day; titrated to a maximum of 4 mg/day.

Arm type	Experimental
Investigational medicinal product name	Brexpiprazole
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Starting dose of 2 mg/day; titrated to a maximum of 4 mg/day. Adjustments could be made to dosing. Treatment duration was 3 weeks.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Tablet taken daily for 3 weeks.

<b>Number of subjects in period 1</b>	Brexpiprazole	Placebo
Started	163	170
Received at least 1 dose of study drug	162	170
Completed	128	135
Not completed	35	35
Consent withdrawn by subject	23	17
Physician decision	3	1
Adverse event, non-fatal	4	8
Other	-	1
Non-Compliance With Study Drug	-	2
Lost to follow-up	4	4
Lack of efficacy	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Brexpiprazole
Reporting group description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligram (mg)/day; titrated to a maximum of 4 mg/day.	
Reporting group title	Placebo
Reporting group description: Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.	

Reporting group values	Brexpiprazole	Placebo	Total
Number of subjects	163	170	333
Age categorical Units:			

Age continuous Units: Years arithmetic mean standard deviation	44.6 ± 10.7	44.3 ± 12.0	-
Gender categorical Units: Subjects			
Female	85	82	167
Male	78	88	166
Race/Ethnicity, Customized Units: Subjects			
White	90	102	192
Black or African American	70	67	137
American Indian or Alaska Native	1	0	1
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other Race	2	1	3
Race/Ethnicity, Customized Units: Subjects			
Hispanic or Latino	22	17	39
Not Hispanic or Latino	140	153	293
Other Ethnicity	1	0	1

## End points

### End points reporting groups

Reporting group title	Brexpiprazole
Reporting group description: Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligram (mg)/day; titrated to a maximum of 4 mg/day.	
Reporting group title	Placebo
Reporting group description: Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.	

### Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3

End point title	Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3
End point description: The YMRS was utilized to assess a participant's level of manic symptoms. It consists of 11 items: 1) elevated mood, 2) increased motor activity-energy, 3) sexual interest, 4) sleep, 5) irritability, 6) speech (rate and amount), 7) language-thought disorder, 8) content, 9) disruptive-aggressive behavior, 10) appearance, and 11) insight. Seven items are rated on a 0- to 4-scale, while four items (Items 5, 6, 8, and 9) are rated on a 0- to 8-scale with 0, 2, 4, 6, and 8 being the possible scores (twice the weight of the other items). For all items, 0 is the "best" rating and the highest score (4 or 8) is the 'worst' rating. The YMRS total score is the sum of ratings for all 11 items; therefore, possible total scores range from 0 to 60, with higher scores signifying more severe manic symptoms. Comparison between treatment groups was carried out using mixed-effect model repeated measure (MMRM).	
End point type	Primary
End point timeframe: Baseline, Week 3	

End point values	Brexpiprazole	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128 <sup>[1]</sup>	133 <sup>[2]</sup>		
Units: units on a scale				
least squares mean (standard error)	-12.3 (± 0.73)	-10.7 (± 0.71)		

Notes:

[1] - Participants who had analyzable data at the specified timepoint.

[2] - Participants who had analyzable data at the specified timepoint.

### Statistical analyses

Statistical analysis title	Treatment Difference in YMRS
Comparison groups	Brexpiprazole v Placebo
Number of subjects included in analysis	261
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1011
Method	mixed-effect model repeated measure
Parameter estimate	Treatment difference
Point estimate	-1.62

Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.56
upper limit	0.32

### Secondary: Change From Baseline In Clinical Global Impression-Bipolar (CGI-BP) Severity Score In Mania At Week 3

End point title	Change From Baseline In Clinical Global Impression-Bipolar (CGI-BP) Severity Score In Mania At Week 3
-----------------	-------------------------------------------------------------------------------------------------------

End point description:

The CGI-BP scale refers to the global impression of the participant with respect to bipolar disorder. The scale rates the participant's severity of illness (CGI-BP severity of illness: mania, depression, and overall bipolar illness) based on a 7-point scale: 1 = normal, not at all ill, 2 = minimally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = very severely ill.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 3

End point values	Brexpiprazole	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128 <sup>[3]</sup>	133 <sup>[4]</sup>		
Units: units on a scale				
arithmetic mean (standard deviation)	-1.31 (± 1.22)	-1.06 (± 1.09)		

Notes:

[3] - Participants who had analyzable data at the specified timepoint.

[4] - Participants who had analyzable data at the specified timepoint.

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 (after dosing) through 6 weeks (3 weeks treatment, 3 weeks safety follow-up).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.1
--------------------	------

### Reporting groups

Reporting group title	Brexpiprazole
-----------------------	---------------

Reporting group description:

Brexpiprazole was administered orally with flexible dosing from 2 to 4 milligram (mg)/day; titrated to a maximum of 4 mg/day.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Matching placebo was administered orally in the same way as brexpiprazole to maintain the blind.

Serious adverse events	Brexpiprazole	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 162 (0.00%)	3 / 170 (1.76%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Nervous system disorders			
Epilepsy			
subjects affected / exposed	0 / 162 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Mania			
subjects affected / exposed	0 / 162 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	Brexpiprazole	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 162 (19.75%)	28 / 170 (16.47%)	
Nervous system disorders			
Akathisia			
subjects affected / exposed	13 / 162 (8.02%)	4 / 170 (2.35%)	
occurrences (all)	14	4	
Dizziness			
subjects affected / exposed	5 / 162 (3.09%)	1 / 170 (0.59%)	
occurrences (all)	5	1	
Headache			
subjects affected / exposed	10 / 162 (6.17%)	18 / 170 (10.59%)	
occurrences (all)	12	19	
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	6 / 162 (3.70%)	5 / 170 (2.94%)	
occurrences (all)	6	5	
Nausea			
subjects affected / exposed	2 / 162 (1.23%)	7 / 170 (4.12%)	
occurrences (all)	2	8	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	5 / 162 (3.09%)	2 / 170 (1.18%)	
occurrences (all)	6	2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 December 2017	<ul style="list-style-type: none"><li>• Remove an incorrect exclusion criteria of <math>\geq 30\%</math> decrease in YMRS between screening and baseline</li><li>• Add clarifying details on administration of the Clinical Global Impressions – Bipolar Scale assessment</li><li>• Add information on retesting participants with elevated lithium, valproate, or carbamazepine at screening</li><li>• Add information on use of anticholinergics</li><li>• Update the efficacy scales in the appendices to match the licensed versions currently available</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None
------

Notes: